The strong interest in the investigation of CMS in metastatic CRC has to some extent been driven by its potential treatment prediction value, including the biological rationale for differential sensitivity to standard anticancer agents targeting EGFR or VEGF. Here, EGFR is linked to colorectal carcinoma.